Enzymotec is Granted with a New Israeli Patent for CardiaBeat

CardiaBeat efficacy in reducing CVD risk factors was evaluated in several clinical trials. The ingredient has additional pending patents around the world and it has already gained a NDI status in the US and a novel food approval in the European Union.

27/01/09 Enzymotec has announced that it has received the Israel patent office approval for CardiaBeat composition and production process. The patent entitled "Fractionation of phytosterol esters in oil" (IL 162764) was granted on 08.11.08 following approvals from New Zealand and China patent offices.

CardiaBeat is a lipid-regulating agent, composed of plant sterol esters of Omega-3 fatty acids in an Omega-3 glyceride matrix. CardiaBeat efficacy in reducing CVD risk factors was evaluated in several clinical trials. The ingredient has additional pending patents around the world and it has already gained a NDI status in the US and a novel food approval in the European Union.

CardiaBeat was launched successfully in several countries around the world including in Israel by Teva pharmaceuticals under the brand name Phyto-Guard and in India by Elder pharmaceuticals under the brand name PhytOmega.

As part of its strategy, Enzymotec continues to invest efforts in order to strengthen its IP position. Numerous patents covering the process, efficacy, health benefits and composition of the  innovative  products are pending around the world.

Enzymotec is a developer and manufacturer of innovative, lipid-based biofunctional solutions for orthomolecular medicine, PS dietary supplements and advanced infant nutrition. Key products are: Sharp line of products- phosphatidylserine based ingredients for cognitive improvement, InFat - structured fat for infant formulas, CardiaBeat offering a broad health effect to reduce CVD risks and Krill Oil+.